Topics

PubMed Journals Articles About "Moffitt Researchers Identify Effective Drug Combination Against Uveal" - Page: 4 RSS

01:58 EDT 1st April 2020 | BioPortfolio

Moffitt Researchers Identify Effective Drug Combination Against Uveal PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Moffitt Researchers Identify Effective Drug Combination Against Uveal articles that have been published worldwide.

More Information about "Moffitt Researchers Identify Effective Drug Combination Against Uveal" on BioPortfolio

We have published hundreds of Moffitt Researchers Identify Effective Drug Combination Against Uveal news stories on BioPortfolio along with dozens of Moffitt Researchers Identify Effective Drug Combination Against Uveal Clinical Trials and PubMed Articles about Moffitt Researchers Identify Effective Drug Combination Against Uveal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Moffitt Researchers Identify Effective Drug Combination Against Uveal Companies in our database. You can also find out about relevant Moffitt Researchers Identify Effective Drug Combination Against Uveal Drugs and Medications on this site too.

Showing "Moffitt researchers identify effective drug combination against uveal" PubMed Articles 76–100 of 29,000+

Effective publication strategies in clinical research.

Researchers in Europe are increasingly assessed by their publication metrics. To uncover the effect of quantitative assessment on the publication strategies of clinical researchers in Denmark, we interviewed 9 senior researchers at the Department of Clinical Research at the University of Southern Denmark with the lowest and highest values for a, as defined by Hirsch. Our aim is to investigate the importance of these metrics to their academic careers: h-index, number of publications, number of citations, int...


Integrated analyses identify potential prognostic markers for uveal melanoma.

Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, which has a high rate of metastases and can induce vision loss and even death to the patients. To identify suitable prognostic markers of UM for the early detection or prognosis prediction would be an essential step toward successful management of the disease. Herein, we extracted the mRNA expression data along with the clinical information from The Cancer Genome Atlas (TCGA) database. A total of eight co-expression module...

The Q site of cytochrome b is a promiscuous drug target in and .

Available treatments for Chagas' disease and visceral leishmaniasis are inadequate and there is a pressing need for new therapeutics. Drug discovery efforts for both diseases principally rely upon phenotypic screening. However, the optimisation of phenotypically-active compounds is hindered by a lack of information regarding their molecular target(s). To combat this issue we initiate target deconvolution studies at an early stage. Here, we describe comprehensive genetic and biochemical studies to determine ...


Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS).

Fluoroquinolones, clarithromycin, linezolid, tigecycline, cefditoren, doxycycline, and trimethoprim-sulfamethoxazole are known to be associated with hypoglycemia, but few studies have considered concomitant glucose-lowering medications.

Scleritis With Uveal Effusion From Alirocumab.

3D printing for oral drug delivery: a new tool to customize drug delivery.

The involvement of recent technologies, such as nanotechnology and three-dimensional printing (3DP), in drug delivery has become the utmost importance for effective and safe delivery of potent therapeutics, and thus, recent advancement for oral drug delivery through 3DP technology has been expanded. The use of computer-aided design (CAD) in 3DP technology allows the manufacturing of drug formulation with the desired release rate and pattern. Currently, the most applicable 3DP technologies in the oral drug d...

Applying drug synergy metrics to oncology combination screening data: agreements, disagreements and pitfalls.

Synergistic drug combinations are commonly sought to overcome monotherapy resistance in cancer treatment. To identify such combinations, high-throughput cancer-cell-line combination screens are performed; and synergy is quantified using competing models based on fundamentally different assumptions. Here, we compare the behaviour of four synergy models, namely Loewe additivity, Bliss independence, highest single agent and zero interaction potency, using the Merck oncology combination screen. We evaluate agre...

A Chirality-Dependent Action of Vitamin C in Suppressing KRAS Mutant Tumor Growth by the Oxidative Combination: Rationale for Cancer Therapeutics.

Kirsten rat sarcoma (KRAS) mutant cancers, which constitute the vast majority of pancreatic tumors, are characterized by their resistance to established therapies and high mortality rates. Here, we developed a novel and extremely effective combinational therapeutic approach to target KRAS mutant tumors through the generation of a cytotoxic oxidative stress. At high concentrations, Vitamin C (VC) is known to provoke oxidative stress and selectively kill KRAS mutant cancer cells, although its effects are limi...

Current discovery strategies for hepatocellular carcinoma therapeutics.

: The global incidence of hepatocellular carcinoma (HCC) is not expected to decline significantly over the next 30 years. And although the latest gene sequencing studies have established its genetic map, the potentially targetable drivers of HCC are, so far, difficult to identify. To date, only seven drugs have been approved by the FDA for unresectable HCC treatment; thus, effective therapeutic breakthroughs are still needed urgently.: In this review, the authors discuss both genetic and epigenetic alterati...

The newest treatments for uveal melanoma.

Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets.

Despite huge efforts made in academic and pharmaceutical worldwide research, current anticancer therapies achieve effective treatment in a limited number of neoplasia cases only. Oncology terms such as big killers - to identify tumours with yet a high mortality rate - or undruggable cancer targets, and chemoresistance, represent the current therapeutic debacle of cancer treatments. In addition, metastases, tumour microenvironments, tumour heterogeneity, metabolic adaptations, and immunotherapy resistance ar...

In situ condensation of an anti-cancer drug into fibrin gel enabling effective inhibition of tumor cell growth.

We show herein the highly effective inhibition of tumor cell growth using a gel consisting of a fibrin polymer formed with the in situ condensation of a camptothecin (CPT) derivative as an anti-cancer drug, which is efficiently conveyed with a carrier aptamer from a solution to the gel in a phenomenon, called selective oligonucleotide entrapment in fibrin polymers (SOEF).

Moving into an urban drug scene among people who use drugs in Vancouver, Canada: Latent class growth analysis.

Urban drug scenes are characterized by high prevalence of illicit drug dealing and use, violence and poverty, much of which is driven by the criminalization of people who use illicit drugs (PWUD) and the associated stigma. Despite significant public health needs, little is understood about patterns of moving into urban drug scenes among PWUD. Therefore, we sought to identify trajectories of residential mobility (hereafter 'mobility') among PWUD into the Downtown Eastside (DTES), an urban neighbourhood with ...

Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent.

The Liver is the most common organ for metastasis for various cancers, including uveal melanoma, the most common primary intraocular tumor. Uveal melanoma metastasizes to the liver in ~90% of patients, and results in death in almost all cases due to late detection and lack of effective treatment. There is a pressing unmet medical need to develop MRI contrast agents and imaging methodologies with desired sensitivity and specificity to overcome the high heterogeneous background and in vivo properties as well ...

Development of the predicted and standardized carbapenem usage metric: Analysis of the Japanese Diagnosis Procedure Combination payment system data.

This study aimed to develop a metric for standardized and predicted carbapenem consumption using the Diagnosis Procedure Combination payment system database and patients' characteristics. Based on Diagnosis Procedure Combination data analysis, the developed metric will provide useful benchmarks that stewardship programs can use to help drive improvements.

The pre-M1 helix controls NMDA receptor gating.

Researchers identify key residue in GluN2A subunit that may regulate channel opening by organizing a network of aromatic amino acids.

Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.

Early diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as gemcitabine and paclitaxel. Therefore, novel strategies that lower the effective dose and improve safety margins could enhance the effect of these drug combinations. To this end, we developed and evaluated a novel drug combinati...

Need for sustainable approaches in antileishmanial drug discovery.

Leishmaniasis is a neglected parasitic disease for which the current antileishmania therapeutics are hampered by drug toxicity, high cost, need for parenteral administration, increasing treatment failure rates, and emergence of drug resistance. The R&D pipeline had run fairly dry for several years, but fortunately some new drug candidates are now under (pre)clinical development. Identification of novel drugs will nevertheless remain essential to adequately sustain and improve effective disease control in th...

How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?

Given the extensive development of new molecules over the last 10 years, regulatory authorities (RAs) have been intensively working on evaluating how to identify and manage "innovative" drugs. The purpose of this article is to analyze whether RAs have procedures capable of ensuring access to innovative drug therapies and to understand what criteria RAs around the world (Europe, USA, Canada, Australia, and Japan) use to identify innovative drugs, comparing the different strategies and tools used to prioritiz...

Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma.

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety.

In HIV-positive population, a paradigm shift from three-drug regimens to dolutegravir-based two-drug regimens as both initial and switch treatment approach is beginning to take place, virologically supported by the availability of new, potent drugs with high genetic-barrier that allow to overcome, at least in certain conditions, the dogma of three-drug regimens in HIV-effective therapy. Indeed, there is increasing evidence on their excellent and sustained long-term effectiveness and safety, that this manusc...

HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.

Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to identify patients at increased risk for development of anti-drug antibodies would facilitate selection of therapy and use of preventative strategies.

Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma-Reply.

Local recurrence of uveal melanoma after proton beam therapy.

New paradigm for expediting drug development in Asia.

Some Asian regulators currently require Phase I data in Asians before joining global Phase II/III trials. Here, we discuss inherent limitations of Phase I ethnic sensitivity studies (ESS) to identify potential interethnic differences. We review recent new drug applications (NDAs) for Japan and China to critically assess the value of separate ESSs in Asian populations. Given that the observed value of ESS was limited, we propose a new global drug development paradigm: if relevant safety, pharmacokinetic (PK)...


Quick Search